3.4 | Outcomes
The treatment was 90% (36 of 40) effective in the CIV group and 94% (47 of 50) in the IIV group. Four patients in the CIV group and 3 patients in the IIV group died because of hematological malignant diseases which were complicated with infections by multiple pathogens like fungi and viruses(57.1%, 4/7), refractory shock (28.6%, 2/7), and severe brain dysfunction (14.3%, 1/7). There was no significant difference in mortality between the two groups (P = 0.481).